|
Market Closed -
London S.E.
11:35:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 0.1750 GBX | 0.00% |
|
0.00% | -12.50% |
| 10-19 | Cora Gold shareholder Eagle Eye restructures holding | AN |
| 10-19 | TheraCryf Completes Preclinical Safety Studies for Orexin-1 Addiction Drug Candidate | MT |
| Market Cap | 6.4M 5.71M 5.28M 4.78M 8.95M 607M 9.09M 63.49M 25.14M 318M 24M 23.49M 1B | P/E 2027 * |
-1.97x | P/E 2028 * | -2.21x |
|---|---|---|---|---|---|
| Enterprise Value | 6.33M 5.65M 5.22M 4.73M 8.85M 601M 9M 62.81M 24.87M 315M 23.74M 23.24M 992M | EV / Sales 2027 * |
-
| EV / Sales 2028 * | - |
| Free-Float |
64.1% | Yield 2027 * |
-
| Yield 2028 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| EVG | Delayed | |
Deutsche Boerse AG
| 8EV | Delayed |
Last Transcript: Theracryf Plc
| Current month | -2.78% | ||
| 3 months | -16.67% | ||
| 6 months | -32.69% | ||
| Current year | -12.50% |
| 1 week | 0.17 |  | 0.19 |
| 1 month | 0.16 | | 0.19 |
| Current year | 0.16 | | 0.27 |
| 1 year | 0.16 | | 0.27 |
| 3 years | 0.16 | | 2.1 |
| 5 years | 0.16 | | 7.8 |
| 10 years | 0.16 | | 30.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 64 | 2020-09-30 |
Toni Haenninen
DFI | Director of Finance/CFO | - | 2023-09-04 |
Glen Clack
CTO | Chief Tech/Sci/R&D Officer | - | 2021-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Alan Barge
BRD | Director/Board Member | - | 2015-10-13 |
Huw Jones
BRD | Director/Board Member | 64 | 2020-09-30 |
Toni Haenninen
BRD | Director/Board Member | - | 2023-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/16/25 | Tracarta Ltd.
| Buy | Company | 7,342,296 | 0.3448% | |
| 5/22/25 | Others | Director | 422,727,272 | 19.8499% | ||
| 3/4/25 | Buy | Chief Operating Officer | 1,500,000 | 0.2945% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | -16.67% | -90.54% | 6.4M | |
| +2.41% | +0.29% | +42.02% | +71.57% | 64.69B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.78B | |
| +0.57% | +4.60% | +10.07% | +92.86% | 53.49B | |
| +0.37% | +4.67% | +27.03% | +52.07% | 45.98B | |
| -1.21% | +2.32% | +21.80% | +123.81% | 42.94B | |
| -0.37% | +5.07% | +249.91% | +918.74% | 40.08B | |
| +0.05% | +0.21% | +18.26% | +58.53% | 33.52B | |
| -0.38% | +5.68% | +36.43% | +27.54% | 23.67B | |
| +1.19% | -4.98% | +29.01% | -0.65% | 23.97B | |
| Average | +0.25% | +2.17% | +42.89% | +132.74% | 38.31B | |
| Weighted average by Cap. | +0.39% | +2.73% | +47.57% | +158.57% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.96M -2.64M -2.44M -2.21M -4.13M -281M -4.2M -29.34M -11.62M -147M -11.09M -10.86M -463M | -2.96M -2.64M -2.44M -2.21M -4.13M -281M -4.2M -29.34M -11.62M -147M -11.09M -10.86M -463M |
| Net Debt | -68.93K -61.55K -56.86K -51.53K -96.41K -6.54M -98K -684K -271K -3.43M -259K -253K -10.81M | 3.02M 2.7M 2.49M 2.26M 4.22M 287M 4.29M 29.98M 11.87M 150M 11.33M 11.09M 474M |
Employees
9
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-23 | GBX 0.1750 | 0.00% | 2,812,681 |
| 26-10-22 | GBX 0.1750 | -2.78% | 6,741,306 |
| 26-10-21 | GBX 0.1800 | 0.00% | 44,939 |
| 26-10-20 | GBX 0.1800 | 0.00% | 9,155,686 |
| 26-10-19 | GBX 0.1800 | +2.86% | 2,385,729 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002341USD
Average target price
0.0159USD
Spread / Average Target
+578.82%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- EVG Stock
Select your edition
All financial news and data tailored to specific country editions
